Pay in 4 interest-free payments of $5.84 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
The incremental number of QALYs associated with SGLT2i use was projected at 29,357, and widespread use of SGLT2is was projected to lead to an incremental healthcare cost of AU$0.3 billion, resulting in an ICER of AU$8878 per QALY gained
4.88 1.78 mIU/ml, p=0.009) at the end of the intervention
Of 159,000 people with type 2 diabetes who were taking these drugs, 35 people (0.04%) developed NAION, compared with 19 patients (0.02%) in the comparison group
Therapeutic blockade of inflammation in severe COVID-19 infection with intravenous N-acetylcysteine
![Fragment [1-25]-Tirzepatide](https://www.daicelpharmastandards.com/wp-content/uploads/2025/04/dcti-d-571.png)
US$ 26.82
US$ 23.17
US$ 20.74
US$ 28.83
US$ 24.00
US$ 25.57
US$ 26.18
US$ 27.21
US$ 26.80
